Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older-Reference-Cited by-同舟云学术

Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older

Published:2016-06-08 Issue:1 Volume:89 Page:91-98
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:J. Med. Virol.

Author:

Akuta Norio¹,Sezaki Hitomi¹,Suzuki Fumitaka¹,Kawamura Yusuke¹,Hosaka Tetsuya¹,Kobayashi Masahiro¹,Kobayashi Mariko²,Saitoh Satoshi¹,Suzuki Yoshiyuki¹,Arase Yasuji¹,Ikeda Kenji¹,Kumada Hiromitsu¹

Affiliation:

1. Department of Hepatology; Okinaka Memorial Institute for Medical Research; Toranomon Hospital; Tokyo Japan

2. Liver Research Laboratory; Toranomon Hospital; Tokyo Japan

Funder

Ministry of Health, Labour and Welfare, Japan

Publisher

Wiley

Subject

Infectious Diseases,Virology

Reference21 articles.

1. Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma;Akuta;J Med Virol,2008

2. Determination of reliability criteria for liver stiffness evaluation by transient elastography;Boursier;Hepatology,2013

3. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders;Chayama;Hepatology,2012

4. Projecting future complications of chronic hepatitis C in the United States;Davis;Liver Transpl,2003

5. Antiviral activity and resistance of HCV NS5A replication complex inhibitors;Gao;Curr Opin Virol,2013

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Direct‑acting antiviral treatment is safe and effective for chronic HCV patients with psychiatric disorders;Experimental and Therapeutic Medicine;2023-07-07

2. Efficacy and safety of direct‐acting antiviral therapy for hepatitis C virus in elderly patients (≥65 years old): A systematic review and meta‐analysis;Journal of Viral Hepatitis;2022-04-06

3. Effectiveness of Direct-Acting Antivirals in Treatment of Elderly Egyptian Chronic Hepatitis C Patients;Gastroenterology Insights;2021-07-17

4. Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C;Biomedicines;2021-06-08

5. Characteristics of patients aged over 75 years with hepatitis C virus infection treated with direct‐acting antivirals in Japan: Evidence based on the nationwide, real‐world database in Japan;Hepatology Research;2021-03